Bullish case
$10 to $12
More likely if Grifols delivers consistent free cash flow to reduce net debt, immunoglobulin demand stays strong, plasma collection costs moderate, and the market re-rates the stock to a P/E near 15x.
Grifols S.A. research snapshot
GRFS AI Stock Analysis
GRFS AI stock analysis sees Grifols as a leading global plasma biopharma company with irreplaceable collection and fractionation infrastructure, but the investment case is dominated by a roughly $10 billion net debt load from acquisitions. At the July 12, 2026 data cutoff, the mechanically checked market capitalization was about $6.11 billion using a $7.16 reference price. The trailing P/E of 10.4x and EV/Revenue of 2.2x reflect the market pricing in both the IVIG demand tailwind and the refinancing, margin, and accounting risks that followed the 2024 Gotham City Research report. Whether the deleveraging plan, free cash flow generation, and operational turnaround can restore confidence is the central question. This page is an informational research tool and is not investment advice.
Current price
$7.16
Market cap
$6.11 billion
AI score
58 / 100
Rating
Valuable plasma assets under a heavy debt burden
Trend status
Near 52-week low with high leverage risk
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- B-level information richness. Grifols publishes annual reports, quarterly results, SEC filings as an ADR (20-F), and plasma industry data. However, the dual Spanish and US listing, the complex capital structure, and the accounting controversy reduce data clarity relative to a plain-vanilla US-listed company.
- bias Check
- The main AI bias risk is to underestimate the balance-sheet leverage because the plasma business appears stable. The analysis separates the operating quality of Biopharma from the debt and accounting risks.
- ai Confidence
- High for reported financials and published plasma market data; medium for the deleveraging timeline and scenario outcomes.
- investment Certainty
- Low to medium. The plasma moat and immunoglobulin demand are durable, but the net debt ratio, interest coverage, and contingent liabilities from the accounting investigation create a wide range of possible outcomes.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Grifols is the world third-largest plasma fractionator after CSL and Takeda. Its revenue is primarily recurring immunoglobulin and albumin sales backed by a proprietary plasma collection network in the US and Europe. | High |
| Moat | The plasma collection infrastructure, fractionation know-how, regulatory licenses, long hospital contracts, and economies of scale create substantial barriers. New entrants face 5-10 year build timelines. | High |
| Management | The founding Grifols family retains control and key management roles. Capital allocation has been aggressive, with large debt-financed acquisitions (Biotest, remaining stake in Grifols Diagnostic). The post-2024 accounting review has forced a more conservative approach. | Medium |
| Financial trend | TTM revenue of $7.44 billion with a 5.6% profit margin. Levered free cash flow of $887 million is positive, but interest expense on $10+ billion in net debt absorbs a significant share of operating income. | Medium |
| Valuation | At the verified reference price, GRFS trades at 10.4x TTM earnings, 0.80x book value, and 6.9x levered free cash flow. The enterprise value of $16.3 billion represents 2.2x revenue and 8.9x EBITDA. | Medium |
| Technical trend | The stock is near the bottom of its 52-week range ($6.96 to $11.14) and has lost over 20% year to date. Momentum and volume suggest continuing caution. | Medium |
| Risk level | Elevated. The combination of high net debt, interest rate exposure, accounting controversy overhang, ADR complexity, and plasma collection cost inflation creates a riskier profile than the biopharma sector average. | Medium-high |
| AI confidence | Reported financials and plasma industry data are well documented. The accounting issues, refinancing terms, and outcome contingent on execution are inherently uncertain. | Medium |
| Investment certainty | Low. The underlying plasma business is durable, but the capital structure risk dominates the near to medium term. Certainty is conditional on observable deleveraging progress. | Low to medium |
GRFS AI stock forecast
GRFS AI Stock Forecast Scenarios
The GRFS AI stock forecast uses three-year scenario ranges from the $7.16 reference price, not a point target. The ranges are outputs of an EPS and multiple framework using $0.69 TTM diluted EPS. They can be wrong and should be refreshed after earnings, debt refinancing updates, free cash flow trends, and operational developments.
Base case
$7 to $9
More likely if revenue grows modestly with IVIG demand, deleveraging proceeds slowly, interest costs remain elevated, and the stock trades near 10-12x earnings with no major accounting surprises.
Bearish case
$4 to $6
More likely if debt refinancing becomes more expensive, an accounting or legal development damages confidence, plasma costs rise, or a recession reduces immunoglobulin procedure volumes.
GRFS AI technical analysis
GRFS AI Technical Analysis
GRFS AI technical analysis uses indicators available around the July 12, 2026 cutoff. This static page does not fetch request-time chart data. Confirm support, resistance, moving averages, momentum, volume, volatility, and invalidation levels in a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Reference price | $7.16 | Reference price used for the July 2026 valuation snapshot from Yahoo Finance. |
| Near support | $6.96 to $7.00 | The 52-week low near $6.96 is a visible planning floor. It is not a guaranteed support level. |
| Near resistance | $8.50 to $9.00 | A recovery above $8.50 would reclaim a prior support-turned-resistance zone and improve the near-term outlook. |
| 50-day moving average | Est. near $8.00 | The 50-day SMA has been declining, consistent with the downward trend. A reclaim above it would be an early improvement signal. |
| 200-day moving average | Est. near $9.00 | A sustained move above this level would suggest a potential trend change. The price has been below it since mid-2025. |
| Momentum | Weak | The RSI was likely in the 35-45 range near the cutoff, consistent with a downtrend approaching oversold conditions. |
| Volume | 677,491 shares 20-day average | Below-average volume on up days and above-average volume on down days would reinforce the bearish near-term picture. |
| Volatility | Moderate | The five-year beta was 1.18 and the 52-week range of $6.96-$11.14 gives a roughly 60% spread from low to high. |
| Invalidation | Close below $6.50 | A decisive close below the 52-week low area with volume would weaken the near-term setup and require a fresh review. |
GRFS AI trading strategy
GRFS AI Trading Strategy Framework
The GRFS AI trading strategy is a rules-based research framework, not personalized advice. Use position sizing, explicit loss limits, live-chart confirmation, and fresh checks of earnings, debt refinancing, cash flow, and accounting developments.
Trend-following setup
Wait for GRFS to reclaim and hold above the $8.50 area with improving volume and momentum, confirming that the downtrend is breaking.
Do not trade the downtrend until a clear breakout is confirmed. A failure at resistance or a new low invalidates the setup.
Mean-reversion setup
If GRFS approaches the $6.96 52-week low without a thesis-breaking negative catalyst, watch for a volume spike and reversal pattern before considering a position.
Set a strict loss limit below $6.50. Do not add to a falling position. The mean-reversion thesis relies on the plasma business value being higher than the distressed price.
Fundamental catalyst setup
Track quarterly earnings, debt refinancing terms, free cash flow, and progress on the deleveraging plan. A positive catalyst could trigger a sharp re-rating given the compressed multiple.
News-driven moves can reverse quickly in a high-debt stock. Take partial profits into strength, and keep position sizes aligned with the elevated risk level.
Investment research summary
Four-master Research Compression
Business essence
Grifols collects plasma from donors in the US and Europe, fractionates it into life-saving protein therapies (immunoglobulins, albumin, clotting factors), and sells them to hospitals and clinics globally. Customers pay for reliable supply of medically necessary, regulation-intensive products.
Moat
The plasma industry has high barriers from donor center infrastructure, FDA and EMA regulatory approvals, fractionation know-how, logistical complexity, and long-term hospital supply contracts. Grifols is one of only three large global fractionators alongside CSL and Takeda.
Munger risk inversion
The thesis can fail if net debt cannot be reduced through free cash flow or asset sales, interest rates stay high, immunoglobulin pricing weakens from new entrants or competitor capacity, plasma collection costs inflate, another accounting or governance issue surfaces, or a major refinancing event forces dilutive equity or distressed terms.
Management
The Grifols family has operated the business for over a century. Capital allocation has been acquisitive, loading the balance sheet with debt from the Biotest deal and other purchases. Post-2024, management has emphasized deleveraging, asset sales, and operational efficiency. The key test is whether they can execute consistently.
Industry trend
Immunoglobulin demand is growing at 6-8% annually driven by aging populations, expanding autoimmune indications, and better diagnosis. Albumin demand is stable. Plasma collection recovered post-COVID. These secular trends are favorable but do not eliminate company-specific balance-sheet risk.
Valuation and margin of safety
At the verified reference price, GRFS trades at 10.4x earnings, 0.80x book value, and 6.9x levered free cash flow. The low multiples reflect the leverage risk. The enterprise value to EBITDA of 8.9x is not distressed and suggests the operating business has substantial value, but that value is mostly pledged to debt holders.
Source-backed data
GRFS Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GRFS reference price | $7.16, cross-checked against Yahoo Finance and financial_rigor.py valuation | Yahoo Finance | July 12, 2026 |
| Market capitalization | $6.11 billion, verified using 853 million shares and $7.16 reference price | Yahoo Finance statistics and financial_rigor.py market-cap check | July 12, 2026 |
| TTM revenue | $7.44 billion | Yahoo Finance key statistics | July 12, 2026 |
| TTM net income | $415 million attributable to common shareholders | Yahoo Finance key statistics | July 12, 2026 |
| TTM EPS and FCF per share | $0.69 diluted EPS and estimated $1.04 levered free cash flow per share | Yahoo Finance key statistics and financial_rigor.py calculation | July 12, 2026 |
| Enterprise value and net debt | EV of $16.25 billion, implying roughly $10.14 billion in net debt (EV minus $6.11B market cap) | Yahoo Finance key statistics | July 12, 2026 |
| Cash and debt | $702 million total cash, total debt/equity of 123.22% | Yahoo Finance key statistics | July 12, 2026 |
Frequently Asked Questions
Read the CSL AI stock analysisRead the TAK AI stock analysisExplore the SNY AI technical analysisUse the AI Stock PickerBuild an AI trading strategyScreen stocks
This GRFS AI stock analysis is an informational tool, not investment advice, an offer, or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available data and assumptions, can be wrong, and may change without notice. Verify current information and consider qualified professional advice before making an investment decision.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Try it
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Try it
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Try it